Becton Dickinson and Company (BDX) Receives Analyst Rating

Becton Dickinson and Company (BDX) : 9 brokerage houses believe that Becton Dickinson and Company (BDX) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Becton Dickinson and Company (BDX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 1.62.

Becton Dickinson and Company (BDX) : The most positive equity analysts on Becton Dickinson and Company (BDX) expects the shares to touch $200, whereas, the least positive believes that the stock will trade at $169 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $185 with an expected fluctuation of $9.29 from the mean.


Also, UBS maintains its rating on Becton Dickinson and Company (NYSE:BDX). The global brokerage major raises the current price target from $182 per share to $195 per share. Analysts at the UBS have a current rating of Buy on the shares. The rating by the firm was issued on August 5, 2016.

Becton Dickinson and Company (NYSE:BDX): After opening at $172.75, the stock dipped to an intraday low of $172.4 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $176.61 and the buying power remained strong till the end. The stock closed at $176.02 for the day, a gain of 1.86% for the day session. The total traded volume was 822,875. The stocks close on the previous trading day was $172.8.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.